Specialty medical injectable drug program, requirements and drug policy updates for May

New specialty medical injectable updates and requirements announced May 2024.

May 28, 2024

Review the following tables to determine changes to our specialty medical injectable drug programs.

SPECIALTY MEDICAL INJECTABLE DRUGS ADDED TO REVIEW AT LAUNCH

For UnitedHealthcare Commercial business

Drug Name Treatment Uses

Winrevair™
(sotatercept-csrk)

Used to treat adults with pulmonary arterial hypertension.

Alyglo™
(immune globulin intravenous, human-stwk)

 

 Used to treat adults with primary humoral immunodeficiency.

Note: Drugs added to Review at Launch may not yet be available in the marketplace.

Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.

For questions, please contact your broker or UnitedHealthcare representative.

Note: Certain specialty medical injectable drug programs and updates will not be implemented at this time for providers practicing in Rhode Island, with respect to certain commercial members, pursuant to the Rhode Island regulation: 230 – RICR-20-30-14. UnitedHealthcare encourages providers practicing in Rhode Island to call in to confirm if prior authorization is required. 

More articles

Employer Page template - More news Experience Fragment

Current employer group client or broker?

Access uhceservices to manage eligibility, view plan documents, request ID cards and more.

Sign in